-
Product Insights
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Lennox-Gastaut Syndrome Clinical Trial Report Overview A total of 254 Lennox-Gastaut Syndrome clinical trials were conducted as of January 2024. The Lennox-Gastaut Syndrome clinical trial report provides a comprehensive understanding of the Lennox-Gastaut Syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       North...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewPost-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024
Empower your strategies with our Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024 report and make more profitable business decisions. Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety medications, and cognitive therapy. The Post-Traumatic Stress Disorder (PTSD) drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewFrontotemporal Dementia (FTD) – Drugs In Development, 2024
Empower your strategies with our Frontotemporal Dementia (FTD) – Drugs In Development, 2024 report and make more profitable business decisions. Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD's exact cause remains unclear, but abnormal protein deposits in the brain are implicated....
-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewProgressive Supranuclear Palsy – Drugs In Development, 2024
Empower your strategies with our Progressive Supranuclear Palsy  – Drugs In Development, 2024 report and make more profitable business decisions. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, and behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications. The Progressive Supranuclear Palsy...
-
Product Insights
NewCluster Headache Syndrome (Cluster Headache) – Drugs In Development, 2024
Empower your strategies with our Cluster Headache Syndrome (Cluster Headache) – Drugs In Development, 2024 report and make more profitable business decisions. Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain; red eyes; runny nose; excessive tearing; and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans. The Cluster Headache Syndrome (Cluster Headache) drugs in development market...
-
Product Insights
NewFibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024
Empower your strategies with our Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs. The Fibromyalgia (Fibromyalgia Syndrome) drugs in development market research report provide comprehensive information...
-
Product Insights
NewNarcolepsy – Drugs In Development, 2024
Empower your strategies with our Narcolepsy – Drugs In Development, 2024 report and make more profitable business decisions. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling. The Narcolepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
NewBatten Disease – Drugs In Development, 2024
Empower your strategies with our Batten Disease – Drugs In Development, 2024 report and make more profitable business decisions. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone, and movement problems. The...